AstraZeneca's Prostate Cancer Treatment Trial Shows Clinically Meaningful Improvement
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week
Astrazeneca (AZN.US) and Amgen (AMGN.US) announced the domestic application for the subcutaneous injection of TSLP monoclonal antibody.
CDE's official website shows that astrazeneca (AZN.US) and amgen (AMGN.US) jointly submitted the marketing application for the TSLP monoclonal antibody Tezepelumab injection.
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
AstraZeneca (AZN) Receives a Buy From Barclays
Amneal Gets FDA Approval for Generic Byetta, Resubmits DHE NDA
Optimism Over Global Healthcare Sector Rises: Jefferies
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
Unusual Options Activity: APO, CMG and Others Attract Market Bets, APO V/OI Ratio Reaches 359.1
EST Nov 21st Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative
Discover AstraZeneca's Journey Toward Decision-Centric Autonomous Planning at the Gartner Supply Chain Planning Summit in Denver
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
CDC Warns Against a Spike in COVID, Flu Cases
U.S. CDC Says Flu, Covid-19, RSV Illnesses Are At Low Levels Right Now Overall In U.S., But We Expect Them To Increase In Coming Weeks; Expects Hospitalizations For Flu And Covid-19 To Start Increasing In Coming Weeks
Tectonic Started at Outperform by Raymond James, TX45 Cited
AstraZeneca Director Invests in Company Shares
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday